Updated:
PRIME SOURCE ENTERPRISES, INC
Gerald Chan's PRIME SOURCE ENTERPRISES, INC invests the Hang Lung Group family fortune with a focus on life sciences and biotech.
PRIME SOURCE ENTERPRISES, INC
PRIME SOURCE ENTERPRISES, INC was established in 1990 as the investment vehicle for Gerald Chan, a member of the Hong Kong-based Chan family that controls Hang Lung Group, one of Asia's largest real estate developers. The family wealth originates from Hang Lung Properties, founded by Chan Tseng-hsi, Gerald's father, which built a dominant portfolio of commercial properties across Hong Kong and mainland China. Gerald Chan, who holds advanced degrees from Harvard in both radiation biology and medical radiological physics, structured his office to reflect a personal, research-driven investment philosophy rather than the diversified, multi-asset approach typical of many large family offices. The firm concentrates heavily on life sciences and biotechnology, deploying capital across venture-stage therapeutics, platform technologies, and healthcare innovation companies. Chan is known for making early, substantial bets on companies where he can leverage his scientific training, often serving as a long-term, patient capital partner. Confirmed investments include Moderna, the mRNA therapeutics company, where he was an early and significant backer prior to its 2018 IPO (per public filings). His portfolio spans geographies with a primary emphasis on the United States, particularly the Boston-Cambridge biotech corridor, and select opportunities in Asia. The office invests directly, through venture funds, and occasionally alongside university spinouts, reflecting a hybrid model of direct financings and limited-partner commitments. The office operates with a deliberately lean structure, consistent with the concentrated, research-intensive nature of its portfolio. While total assets under management are not publicly disclosed, Chan's consistent presence in major biotech financings signals substantial deployable capital. In September 2023, Chan made a $210 million gift to Harvard to endow its School of Public Health, a philanthropic commitment that reflects the scale of the family's wealth and its focus on public health — an adjacent activity to the investing operation (per Harvard Gazette, September 2023). Chan also maintains ties to Morningside Group, the broader family investment platform with offices in Hong Kong and Shanghai. PRIME SOURCE ENTERPRISES, INC stands apart from most family offices through its principal's personal scientific authority — Chan holds a doctorate in biology and a master's in medical radiological physics from Harvard, credentials that allow him to conduct his own deep technical diligence on portfolio companies. This represents a genuine structural edge in an asset class where most allocators depend on third-party scientific advisory boards. The office's investment thesis is inseparable from Chan's own intellectual conviction, making succession and institutionalization a central question as the portfolio matures.
General information
Firm type
Single Family Office
Year founded
1990
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Natick
Corporate office
Natick, MA, United States
Principals
Gerald Chan
Principal
Sector focus
Frequently asked questions
Who runs investment decisions at PRIME SOURCE ENTERPRISES, INC?
Gerald Chan is the principal and directs all investment activity for the office. Chan holds a PhD in biology and a master's in medical radiological physics from Harvard University, giving him the technical background to personally evaluate scientific opportunities. His approach is research-intensive and concentrated, rather than delegated to a large investment committee.
How is PRIME SOURCE ENTERPRISES, INC related to the Hang Lung Group?
The office manages personal and family capital derived from the Hang Lung Group real estate fortune. Gerald Chan's father, Chan Tseng-hsi, founded Hang Lung Group and built its commercial property portfolio across Hong Kong and mainland China. Gerald Chan's brother, Ronnie Chan, leads the Hang Lung Group operating businesses, while Gerald focuses on investment and philanthropic activities through separate vehicles.
What is the firm's investment strategy in life sciences?
PRIME SOURCE ENTERPRISES, INC concentrates on early-stage therapeutics, platform biotech companies, and healthcare innovation, with a long-term, patient capital posture. Chan is known for making substantial bets on companies where his scientific background provides a diligence edge, often investing at the venture stage and holding through public listings. The portfolio spans direct investments, venture fund commitments, and occasional university spinout financings.
How is PRIME SOURCE ENTERPRISES, INC different from Morningside Group?
Morningside Group is the broader Chan family investment platform with a presence in Hong Kong, Shanghai, and other Asian markets, active across venture capital, private equity, and real assets. PRIME SOURCE ENTERPRISES, INC operates as Gerald Chan's personal investment vehicle, with a more concentrated focus on life sciences and biotechnology in the United States. The two entities share family ties but pursue distinct investment programs.
Does the firm participate in fund commitments or only direct deals?
PRIME SOURCE ENTERPRISES, INC uses a hybrid model that includes direct equity investments in private and public biotech companies, limited-partner commitments to venture capital funds, and occasionally co-invests alongside academic institutions. The direct investing program is the most visible component, reflecting Chan's preference for concentrated positions in companies he has personally vetted.
What is the firm's geographic investment focus?
The office is heavily concentrated in the United States, particularly the Boston-Cambridge biotechnology cluster, which aligns with Chan's academic and professional base in Massachusetts. It also selectively evaluates opportunities in Asia, leveraging the family's regional network. The firm does not publicly disclose a formal geographic allocation but the portfolio reflects this U.S.-centric, Boston-heavy orientation.
Does Gerald Chan maintain separate philanthropic structures?
Yes. Chan is a major philanthropist, most notably through a $210 million gift to Harvard University in 2023 to support the Harvard T.H. Chan School of Public Health, named for his late father. His philanthropic giving often targets public health, education, and scientific research, operating through separate charitable entities distinct from the investment office's commercial activities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: